You have no items in your shopping cart.
Recombinant SARS-Cov-2 Spike S1 protein (E484Q, L452R, D614G, P681R), His (HEK293)
Description
Research Area
Images & Validation
−| Application Notes |
|---|
Key Properties
−| Expression System | HEK293 cell |
|---|---|
| Target | Spike glycoprotein |
| Tag | His |
| Endotoxins | Not analyzed |
| MW | 90 kDa |
| Purity | > 90% as determined by SDS-PAGE |
| Protein Sequence | 14-685/1273 |
Storage & Handling
−| Storage | Stored at -70°C or -20°C. Avoid repeated freeze/thaw cycles. |
|---|---|
| Concentration | > 0.5 mg/ml |
| Expiration Date | 6 months from date of receipt. |
| Disclaimer | For research use only |
Alternative Names
−Similar Products
−SARS-CoV-2 Spike S1 Protein (T95I & G142D & E154K & L452R & E484Q & D614G & P681R, His & Avi), Biotinylated [orb1953646]
98.00%
78.39 kDa (predicted); 110.06 kDa (reducing condition, due to glycosylation)
20 μgSARS-CoV-2 Spike S1 Protein (T19R & G142D & L452R & E484Q & D614G & P681R, His) [orb1953669]
98.00%
76.62 kDa (predicted); 90.30 kDa (reducing condition, due to glycosylation)
100 μgSARS-CoV-2 Spike S1 Protein (T19R & G142D & L452R & E484Q & D614G & P681R, His & Avi), Biotinylated [orb1953679]
98.00%
78.43 kDa (predicted); 116 kDa (reducing condition, due to glycosylation)
20 μgSARS-CoV-2 Spike S1 Protein (T95I & G142D & E154K & L452R & E484Q & D614G & P681R, His) [orb1953687]
98.00%
76.58 kDa (predicted); 106.41 kDa (reducing condition, due to glycosylation)
100 μgSARS-CoV-2 Spike S1 Protein (E154K & L452R & E484Q & D614G & P681R, His) [orb1953754]
98.00%
76.5 kDa (predicted); 107.9 kDa (reducing condition, due to glycosylation)
100 μg

Quality Guarantee
Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].


